Blog: ANGIODYNAMICS INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) –

Item 7.01 – Regulation FD Disclosure.

On January 10, 2022, James Clemmer, President and Chief Executive Officer of
AngioDynamics, Inc. (“AngioDynamics”), and Stephen Trowbridge, Executive Vice
President and Chief Financial Officer of AngioDynamics, will present at the 24th
Annual Needham Virtual Growth Conference. The presentation slides are furnished
herewith as Exhibit 99.1.

The presentation slides furnished pursuant to Item 7.01 of this Form 8-K
(including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or
otherwise subject to the liabilities under that Section. Furthermore, the
presentation slides shall not be deemed to be incorporated by reference into any
filing under the Securities Act of 1933, as amended, or the Exchange Act.

Forward-Looking Statements

This document and its attachments contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. All statements
regarding AngioDynamics’ expected future financial position, results of
operations, cash flows, business strategy, budgets, projected costs, capital
expenditures, products, competitive positions, growth opportunities, plans and
objectives of management for future operations, as well as statements that
include the words such as “expects,” “reaffirms,” “intends,” “anticipates,”
“plans,” “believes,” “seeks,” “estimates,” “project”, “optimistic,” or
variations of such words and similar expressions, are forward-looking
statements. These forward-looking statements are not guarantees of future
performance and are subject to risks and uncertainties. Investors are cautioned
that actual events or results may differ materially from AngioDynamics’
expectations, express or implied. Factors that may affect the actual results
achieved by AngioDynamics include, without limitation, the scale and scope of
the COVID-19 global pandemic, the ability of AngioDynamics to develop its
existing and new products, technological advances and patents attained by
competitors, infringement of AngioDynamics’ technology or assertions that
AngioDynamics’ technology infringes the technology of third parties, the ability
of AngioDynamics to effectively compete against competitors that have
substantially greater resources, future actions by the FDA or other regulatory
agencies, domestic and foreign health care reforms and government regulations,
results of pending or future clinical trials, overall economic conditions
(including inflation and labor shortages), the results of on-going litigation,
challenges with respect to third-party distributors or joint venture partners or
collaborators, the results of sales efforts, the effects of product recalls and
product liability claims, changes in key personnel, the ability of AngioDynamics
to execute on strategic initiatives, the effects of economic, credit and capital
market conditions, general market conditions, market acceptance, foreign
currency exchange rate fluctuations, the effects on pricing from group
purchasing organizations and competition, the ability of AngioDynamics to
integrate acquired businesses, as well as the risk factors listed from time to
time in AngioDynamics’ SEC filings, including but not limited to its Annual
Report on Form 10-K for the year ended May 31, 2021 and its Quarterly Report on
Form 10-Q for the fiscal period ended August 31, 2021. AngioDynamics does not
assume any obligation to publicly update or revise any forward-looking
statements for any reason.


Item 9.01 – Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.      Description

  99.1           Presentation slides for the 24th Annual Needham Virtual Growth
                 Conference, dated January 10, 2022


© Edgar Online, source Glimpses

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s